S

Science 37

Virtual site platform for decentralized trials

Overview

Science 37 runs a clinical research platform focused on decentralized (site-less) trials, offering technology and services to pharma, biotech, and CROs, centered on its Metasite platform and remote patient recruitment. Its Metasite virtual site connects patients at home with telemedicine physicians, mobile nurses, and coordinators for remote visits, data capture, and eConsent, with Metasite Rescue available to accelerate enrollment and standardized workflows to improve data quality and diversity. The company differentiates itself by providing a single unifying, site-less platform that enables fully remote participation and removes geographic barriers, integrating telemedicine, remote monitoring, and digital consent. Its goal is to make clinical trials more accessible and efficient by expanding patient access, boosting enrollment diversity, and delivering faster, higher-quality trial data using a unified digital trial platform.

Work here?Claim your company

About Science 37

Simplify's Rating
Why Science 37 is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & AnalyticsEnterprise SoftwareHealthcare

Company Size

201-500

Company Stage

IPO

Headquarters

Morrisville, NC

Founded

2014

Get referred to Science 37

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • July 2026 PatientsLikeMe partnership expands patient acquisition across underserved disease communities.
  • November 2026 BioTechnology Innovation of the Year strengthens sponsor credibility and sales pitches.
  • March 2026 pediatrics launch and May 2026 Tufts publication validate operational performance.

What critics are saying

  • Science 37 terminated North Carolina JDIG incentives in January 2025 after missing jobs.
  • The 2024 layoffs cut 73 employees, signaling continued cost pressure and operating shrinkage.
  • If sponsor demand softens again, eMed can absorb Science 37’s standalone identity entirely.

What makes Science 37 unique

  • Science 37 operates one nationwide direct-to-patient site, not fragmented local sites.
  • Its 2026 Tufts CSDD study showed 20–30% enrollment contribution per trial.
  • The 2026 Pediatrics Department brings home- and school-based trials to families.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$447.5M

Above

Industry Average

Funded Over

9 Rounds

Acquisition funding comparison data is currently unavailable. We're working to provide this information soon!
Acquisition Funding Comparison Coming Soon

Benefits

  • Remote Work Options
  • Flexible Work Hours

Stock Price

Growth & Insights and Company News

6 month growth

-2%

1 year growth

-2%

2 year growth

-9%
TMCnet
Nov 10th, 2026
Science 37 Named a BioSpace 2027 Best Place to Work

Science 37 Named a BioSpace 2027 Best Place to Work TMCnet News [November 10, 2026] | / | Science 37 Named a BioSpace 2027 Best Place to Work MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) - Science 37, a nationwide direct-to-patient clinical research site, today announced that it has been named a BioSpace 2027 Best Place to Work, an honor shaped by the voices of its own employees. The recognition reflects the people who have built an innovative, radically transparent culture and used it to reimagine how site conduct and clinical research are delivered, all while maintaining rigorous standards of quality. Delivering on Science 37's mission to expand access to clinical research takes a special kind of team. Bringing clinical trials directly into patients' homes calls on employees to challenge conventional thinking, raise problems openly, and collaborate across disciplines to develop new solutions. Transparency, accountability, compassion, and a commitment to failing forward guide how Science 37 teams work, innovate, and continuously improve. Science 37 employees apply these same principles to their own workplace and to the sponsor relationships they build. Initiatives such as employee-led Show & Tell sessions, collaborative performance development, and formal upward feedback give every team member a voice in how Science 37 grows. This commitment to transparency, growth, and shared purpose is reflected in a 97.9% year-to-date employee retention rate. The results of that work show up in the company's clinical quality. Science 37 teams have supported multiple FDA inspections tied to regulatory approvals, receiving No Action Indicated (NAI) classifications with zero Form FDA 483 observations. Together, they have supported more than 200 clinical trials, achieving approximately 86% study completion rates and contributing an average of 20-30% of total study enrollment as a single site. "Building a Direct-to-Patient Site and clinical reearch starts with people. Whether it is our employees, patients, or the sponsors we serve, everyone is a stakeholder in challenging conventional thinking," said Tyler Van Horn, CEO of Science 37. "That kind of innovation requires radical transparency, a willingness to question how things are done today, and accountability to each other for continuous improvement. I'm especially proud that we've paired this innovative approach with the clinical quality demonstrated through our regulatory track record. This recognition belongs to the employees who make it possible every day." BioSpace's Best Places to Work recognition is based on feedback from thousands of life sciences professionals, evaluating employers across attributes including innovation, leadership, culture, career growth, and workplace flexibility. About Best Places to Work BioSpace's Best Places to Work recognizes leading life sciences employers based on votes and ratings from industry professionals. For the 2027 recognition, more than 8,000 professionals participated, providing over 2,300 open-ended comments and evaluating organizations across key workplace attributes. About BioSpace BioSpace is the hub for life science news and jobs. Fog Computing World provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Learn more and subscribe at www.biospace.com. About Science 37 Science 37 is a modern clinical research site that delivers trials directly to patients' homes. With nationwide reach and medical licensure across all 50 states, its Direct-to-Patient Site enables sponsors to expand access, improve retention, and enroll more representative patient populations compared to relying solely on a traditional site-based approach. Science 37 operates under a single Form FDA 1572 and a central IRB, supported by centralized medical oversight, research-grade nursing, and specialized direct-to-patient clinical operations. The company has successfully completed multiple FDA inspections resulting in FDA approvals, achieving No Action Indicated (NAI) classifications with zero Form 483 observations. With more than a decade of experience, Science 37 has supported over 200 clinical trials across Phases I-IV and observational studies. Its model consistently delivers strong performance, including approximately 86% completion rates and contributing an average of 20-30% of total study enrollment as a single site. These outcomes have been validated by the Tufts Center for the Study of Drug Development (Tufts CSDD). To learn more, visit www.science37.com or email [email protected]. Media Inquiries Science 37 [email protected] [ Back To TMCnet.com's Homepage] |

Science 37
Nov 5th, 2026
Science 37 Named 2026 "BioTechnology Innovation of the Year" for its Direct-to-Patient Clinical Trial Delivery Model

Science 37 Named 2026 "BioTechnology Innovation of the Year" for its Direct-to-Patient Clinical Trial Delivery Model November 5, 2026

Science 37
Jul 21st, 2026
PatientsLikeMe and Science 37 partner to unlock trial access for interested, eligible patients.

PatientsLikeMe and Science 37 partner to unlock trial access for interested, eligible patients. July 21, 2026 Partnership combines trusted patient communities with flexible trial participation options to help sponsors enroll faster and retain patients. BOSTON, MA and MORRISVILLE, NC - July 21, 2026 - PatientsLikeMe ("PLM") Powered by Fuze Health, a leading patient engagement and health insights platform, and Science 37, the industry-leading patient access company for clinical research, today announced a strategic partnership aimed at helping pharmaceutical and biotechnology sponsors accelerate clinical development. The partnership is designed to get the right patients into the right trials, faster, and make it easier for them to participate. Together, the companies aim to help sponsors shorten enrollment timelines, improve participant retention, and expand access to research opportunities for traditionally underserved and geographically dispersed patient populations. Despite the growing investment in clinical research, many trials continue to miss enrollment timelines because eligible patients are unaware of available studies, uncertain about participation, or face logistical barriers that make enrollment difficult. Through this partnership, PatientsLikeMe and Science 37 aim to address those challenges by connecting patients with research opportunities earlier and making participation more accessible. Together, the companies will aim to provide sponsors with a scalable patient recruitment and engagement solution that: * Identifies, educates, and activates highly relevant patients earlier in the disease journey; * Improves conversion from awareness to enrollment through continuous patient engagement and support; * Enables flexible participation through traditional, hybrid, and decentralized trial models; and * Expands access, improves retention, and reduces burden for patients. "Clinical trial sponsors face real pressures around enrollment timelines, patient retention, protocol complexity, and site performance," said Christopher Renfro-Wallace, COO, PatientsLikeMe. "This partnership addresses those challenges with a more connected activation pathway that makes it easier to find the right patients, enroll them faster and keep them engaged throughout the trial." PLM, through its national patient community, brings condition-specific education, peer engagement, and trusted patient support when engaging patients who may have never before considered a clinical trial as an option. Science 37's Direct-to-Patient trial infrastructure then gives patients flexible ways to participate in the clinical trial, through remote and in-home clinical research capabilities across all 50 States. "The industry doesn't have an awareness problem. It has a connection problem," said Tyler Van Horn, Chief Executive Officer of Science 37. "Millions of patients are interested in advancing research, yet too many never learn about relevant clinical trial opportunities or encounter barriers that prevent participation. By combining PatientsLikeMe's trusted patient communities with Science 37's flexible trial delivery model and nationwide coverage, we're creating a more direct path from patient interest to study participation, helping sponsors accelerate enrollment while expanding access to research." The companies expect the partnership to deliver particular value in studies where patient identification, engagement, and retention are critical to success. This includes rare disease and specialty populations, therapeutic areas with multiple competing trials recruiting simultaneously, geographically dispersed patient populations, and studies with complex protocols or high participant burden. By combining trusted patient engagement with flexible participation models, the partnership helps sponsors overcome some of the most persistent barriers to enrollment and retention. In addition to patient recruitment and enrollment, the partners will explore collaborations around: * Integrating patient insights into protocol and study design decisions * Reducing patient burden and improving the patient experience * Longitudinal retention and adherence programs * Real-world insights and patient experience analytics About PatientsLikeMe Powered by Fuze Health PatientsLikeMe is the leading patient engagement and health insights platform that helps patients navigate their health journeys through shared experience, data, and community. The company supports patient activation, longitudinal engagement, research participation, and real-world insight generation across a broad range of conditions and therapeutic areas. PatientsLikeMe is part of Fuze Health, a technology-powered home health screening, genomics and pharmacy services provider committed to transforming patient experiences and enabling healthcare partners, including care providers, health plans, employers and life sciences companies, to excel in an outcomes-focused system. About Science 37 Science 37 is a modern clinical research site that delivers trials directly to patients' homes. With nationwide reach and medical licensure across all 50 states, its Direct-to-Patient Site enables sponsors to expand access, improve retention, and enroll more representative patient populations compared to relying solely on a traditional site-based approach. Science 37 operates under a single Form FDA 1572 and a central IRB, supported by centralized medical oversight, research-grade nursing, and specialized direct-to-patient clinical operations. The company has successfully completed multiple FDA inspections, resulting in FDA approvals, achieving No Action Indicated (NAI) classifications with zero Form 483 observations. With more than a decade of experience, Science 37 has supported over 200 clinical trials across Phases I-IV and observational studies. Its model consistently delivers strong performance, including approximately 86% completion rates and contributing an average of 20-30% of total study enrollment as a single site. These outcomes have been validated by the Tufts Center for the Study of Drug Development (Tufts CSDD). To learn more, visit www.science37.com or email [email protected]. Media Inquiries Science 37 [email protected]

Associated Press
Mar 17th, 2026
Science 37 launches pediatrics department to bring clinical trials into homes and schools

Science 37 has launched a dedicated Pediatrics Department to expand access to clinical trials for children and families. The company aims to reduce logistical and emotional burdens by bringing specialized trial activities directly into homes or schools, eliminating travel to traditional research sites. The department features dedicated paediatric investigators, research-grade nurses trained in home-based care, and clinical research coordinators supporting caregivers throughout studies. Science 37 has supported over 20 paediatric trials across therapeutic areas including asthma and Prader-Willi Syndrome. In a recent Phase 3 Fragile X Syndrome study, Science 37 was the top-enrolling site, contributing 25% of all patients with a 94% retention rate. The company focuses on designing research that fits into childhood routines whilst maintaining clinical rigour and safety standards.

StockTitan
Sep 16th, 2024
Science 37 Earns Frost & Sullivan's 2024 Global Company of the Year Award for Decentralized Clinical Trials

Science 37, a leader in enhancing patient access to clinical trials, has been awarded Frost & Sullivan's 2024 Global Company of the Year Award for Decentralized Clinical Trials.

Recently Posted Jobs

Sign up to get curated job recommendations

Science 37 is Hiring for 56 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs